Abpro Holdings, Inc. · OTC:ABPO

Abpro — SPAC Merger (January 2024)

47 slides from Abpro's SPAC merger presentation, Jan 22, 2024

  1. Slide 1: Abpro

    Exhibit 99.2 abpro

  2. Slide 2: Disclaimers

    2 Disclaimers This presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Abpro Corporation (“Abpro”) and Atlantic Coastal Acquisition Co

  3. Slide 3: Disclaimers: Additional Information and Where to Find It

    3 Disclaimers Additional Information and Where to Find It This document relates to the Proposed Business Combination between Abpro and ACAB. ACAB filed a registration statement on Form S-4 relating to the Proposed Business Combination (the “Registration Statement”) which will includes a proxy statem

  4. Slide 4: Table of Contents

    44 Transaction Overview Market Forecasts 1 2 Experienced Team Investment Highlights 3 4 Table of Pipeline and Technology Lead Candidates 5 6 Platforms Contents Additional Pipeline Program Development 7 8 Candidates Timeline Appendix 9

  5. Slide 5: Key Presenters

    5 5 Key Presenters Miles Suk Shahraab Ahmad Ian Chan CEO CEO & Co-Founder Board Member Atlantic Coastal Acquisition Abpro Corporation Abpro Corporation Corp. II (ACAB)

  6. Slide 6: Transaction Overview

    6 Transaction Overview Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) plans to conduct a Pro Forma Valuation at Close business combination with Abpro Corporation (“Abpro“) at a purchase price of approximately $500 million (USD millions, except for share data) • Transaction expected to be funde

  7. Slide 7: Risk-adjusted present value of future revenue approximately $1.2 billion

    77 After discounting, the risk-adjusted present value of future revenue from both assets combined is approximately $1.2 billion 1 Present Value Discounted and Risk-Adjusted $1,200 Value Source • Based on weighted average $1,000 cost of capital (WACC) in 2 biotech and pharma Discount 12% • Adjusted u

  8. Slide 8: Two lead assets expected to peak at ~$1.6B combined revenue

    8 Abpro’s two lead assets are expected to peak at ~$1.6B in combined revenue Abpro Revenues WW, Non-Risk-Adjusted $2,000 ABP-201 $1,590 $1,539 $1,500 ABP-102 $1,409 $1,403 $1,250 $1,192 $1,188 $1,175 $1,083 $1,040 $1,006 $952 $1,000 $841 $500 $387 $350 $132 $0 2030 2031 2032 2033 2034 2035 2036 2037

  9. Slide 9: Peak risk-adjusted revenue for ABP-102 and ABP-201 expected $570MM

    9 After adjusting revenues based on each asset’s probability of success, the peak risk adjusted revenue for ABP-102 and ABP-201 is expected to be $570MM Asset PTRS Notes • Historic ophthalmology PTRS Risk Adjusted Revenues ABP-201 40% • Adjusted significantly upward given WW, 2029-2045 identical MOA

  10. Slide 10: Investment Highlights

    10 Investment Highlights Proprietary Antibody Platform Robust Therapeutic Pipeline of Next Generation Candidates ® • Antibody Discovery: DiversImmune 1 Candidate Indication NPV TM • Antibody Engineering: MultiMab • ABP-102(HER2/CD3) Breast and gastric cancer $640 million • ABP-201(VEGF/ANG2) Wet AMD

  11. Slide 11: Experienced Leadership Team

    11 Experienced Leadership Team Ian Chan, MBA Eugene Chan, MD Robert Markelewicz, MD Christian Zapf, JD, MBA Richard Mitrano SVP of Corporate Development SVP of Finance CEO, Co-founder Chairman, Co-founder Chief Medical Officer & General Counsel Brown AB; Harvard MBA Harvard AB; Harvard MD Brown ScB,

  12. Slide 12: Atlantic Coastal Management Team

    12 Atlantic Coastal Management Team Shahraab Ahmad Burt Jordan Jason Chryssicas Tony Eisenberg President Chairman, CEO CFO CSO

  13. Slide 13: Experts on Boards

    13 13 Experts on Boards 1 2 2 Robert Langer, PhD Laurie Glimcher, MD Ron Levy, MD David H. Koch Institute Professor, MIT; President and CEO, Professor and Chief, Founder of Moderna, BIND, Dana-Farber Cancer Institute Division of Oncology, Momenta, AIR, others Stanford School of Medicine 2 2 2 George

  14. Slide 14: Pipeline with Next Generation Candidates

    14 Pipeline with Next Generation Candidates TOTAL INDICATION PROGRAM TARGET DISCOVERY PRECLINICAL IND-ENABLING ADDRESSABLE MARKET 1 DME/Wet AMD Anti-VEGF/ANG2 ABP-201 $10.4 Billion Breast, Gastric 2 Anti-HER2/CD3 ABP-102 $12.1 Billion Cancer 3 Liver Cancer Anti-GPC3/CD3 ABP-110 $12.9 Billion 4 Gastr

  15. Slide 15: Technology Platform

    TECHNOLOGY PLATFORM

  16. Slide 16: DiversImmune Discovery Platform

    ® 16 16 Diversimmune Discovery Platform Features: • Rapid Generation Creates antibody therapies against traditionally Proprietary antibody discovery platform difficult targets that seeks to swiftly produce a diverse array of antibodies Validated by global pharma and research institutions • Target Va

  17. Slide 17: MultiMab Antibody Engineering Platform and TetraBi Format

    TM 17 17 MultiMab Antibody Engineering Platform and TetraBi Format Anticipated Advantages of TetraBi Format: 1 • Bivalent binding to TAA for potentially Enhancing efficacy and safety: fine-tuning antibody product increased efficacy formats for optimal results • Fc modification for reducing toxicity

  18. Slide 18: Lead Programs

    LEAD PROGRAMS • ABP-102 • ABP-201

  19. Slide 19: ABP-102 HER2/CD3 T-Cell Engager

    ABP-102 HER2/CD3 T-Cell Engager Treatment for HER2+ Breast Cancer & Gastric Cancer

  20. Slide 20: ABP-102: Strategic Partnership with Celltrion

    20 20 ABP-102: Strategic Partnership Global Development & with Celltrion Commercialization Partnership Highlights Leading biopharmaceutical company headquartered in Incheon, South Korea; KRX: 068270 Fully Funded Anticipated Development Plan • Celltrion funds all development costs, including preclini

  21. Slide 21: Addressing Unmet Needs in HER2+ Cancers Treatment

    21 21 Addressing Unmet Needs in HER2+ Cancers Treatment: ABP-102 Competitive Landscape 3 ABP-102 vs. Approved Anti-HER2 Therapies $12.1 billion $640 million 2 Projected global HER2+ ABP-102’s Net Present Value ABP-102 ABP-102 1 market size by 2030 Development Fully Funded By collaboration partner Ce

  22. Slide 22: ABP-102: Next generation T-cell engager for HER2+ solid tumors

    HER2 22 22 ABP-102: Next generation T-cell engager for HER2+ solid tumors HER2-high CD3 (Humanized and Cyno Cross-Reactive) Key Characteristics: • Dual-arm affinity-tuned construct for selective killing and cytokine release on HER2-high target cells, with reduced killing and cytokine release on HER2

  23. Slide 23: ABP-201 VEGF/ANG-2 Bispecific Antibody

    ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODY Treatment for Diabetic Macular Edema (“DME”) & Wet Age-related Macular Degeneration (”AMD”)

  24. Slide 24: Addressing Unmet Needs in Wet AMD/DME Treatment

    24 24 Addressing Unmet Needs in Wet AMD/DME Treatment: ABP-201 Competitive Landscape 3 ABP-201 vs. Approved Wet AMD/DME Therapies $10.4 billion $600 million 2 Global Wet AMD market ABP-201’s Net Present Value 1 ABP-201 size projection in 2024 Potential Competitive Advantages: • Unlike Eylea and Luce

  25. Slide 25: ABP-201: Anti-VEGF/ANG2

    25 ABP-201: Anti-VEGF/ANG2 Target Indication: Wet AMD/DME Key Characteristics • Dual inhibition of VEGF and ANG-2 to block angiogenesis ABP-201 • Four high-affinity binding sites for increased potential potency • Dual targeting in single molecule for simultaneous inhibition • Natural antibody struct

  26. Slide 26: ABP-201: Positive Results in Preclinical Models

    26 ABP-201: Positive Results in Preclinical Models Mean total ocular examination scores over 1 Mean Intraocular pressure over time 1 time ABP-201 does not induce significant inflammation or intraocular pressure increases in preclinical models OE Scores range from 0(no abnormalities) to a maximum of

  27. Slide 27: ABP-201 Current Status and Development Plan

    27 27 Current Status: • Investigation New Drug (IND) enabling studies underway Anticipated Development Plan • 1H 2025: File IND application • 2H 2025: Initiate a Phase 1 trial in ABP-201 patients with Wet AMD Development • Following the identification of the maximum tolerated dose (MTD) in Collabora

  28. Slide 28: Additional T-Cell Engagers

    ADDITIONAL T-CELL ENGAGERS ABP-150: Anti-Claudin 18.2/ CD3 against Gastric Cancer ABP-110: Anti-GPC3/CD3 against Liver Cancer

  29. Slide 29: ABP-150: Anti-Claudin18.2/CD3

    29 ABP-150: Anti-Claudin18.2/CD3 Target Indication: Gastric Cancer $13.11 billion Key Characteristics • T-cell engager designed to fight cancer through co-targeting CD3 & Claudin 18.2 Global gastric cancer market 2 size projection by 2029 • Specific for Claudin 18.2, avoiding binding closely related

  30. Slide 30: ABP-150: in vivo Efficacy and Safety Profile in Preclinical Models

    30 ABP-150: in vivo Efficacy and Safety Profile in Preclinical Models 1 Potent in vivo efficacy in gastric cancer ABP-150 is well tolerated in a preclinical tox model 1 xenograft mouse model Body weights Temperatures 24 38.0 ABP ABP 37.5 22 ABP Veh 2500 37.0 0.05 mg/kg ABP-150 20 36.5 0.005 mg/kg AB

  31. Slide 31: ABP-110: Anti-GPC3/CD3

    31 31 ABP-110: Anti-GPC3/CD3 Target Indication: Hepatocellular Carcinoma- Liver Cancer Designed to provide in-vitro T-cell + 2 + 2 HEP3B tumors + CD8 T cells HEPG2 tumors + CD8 T cells dependent cellular cytotoxicity 60 100 (TDCC) against liver cancer cells YP7 x CD3 YP7 x CD3 80 3BN9 x CD3 3BN9 x C

  32. Slide 32: Anticipated Clinical Development Timeline

    32 Anticipated Clinical Development Timeline Timeline 2025 2026 2026 2027 2027 2028 2028 2029 2029 2030 2030 2031 and Beyond 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H ABP-102 BLA Phase 1 Phase 2 Phase 3 BLA- ABP-201 Phase 1 Phase 2 Phase 3 2033 2H BLA- ABP-150 Phase 1 Phase 2 Phase 3 2033 2H BLA- ABP-110 Pha

  33. Slide 33: Appendix

    • Additional Data for Abpro Technology Platform • Additional Key Team Members Appendix • Additional Data for ABP-102(HER2/CD3) • Additional Data for ABP-201(VEGF/ANG2)

  34. Slide 34: Additional Data for Abpro Technology Platform

    Additional Data for Abpro Technology Platform 34

  35. Slide 35: DiversImmune Platform Case Study: Amyloid

    35 35 Diversimmune Platform Case study: Amyloid*: Preclinical results from functional therapeutic antibodies ® generated with DiversImmune platform, via a project for GSK, 1 published in Nature and The New England Journal of 2 Medicine Abpro generated a therapeutic mAb “Abp1” against Amyloid used by

  36. Slide 36: Neutralizing Antibody Discovery Platform

    36 Neutralizing Antibody B cell Cloning Discovery Platform Timeline: < 2 months Neutralizing Target-specific Paired H/L cDNA NGS B Cell isolation Activity memory B cells by barcoding sequencing Convalescent /immunized human Humanized mice subjects A strategy to enrich only the B cells that Cloning a

  37. Slide 37: Anticipated Advantages of TetraBi Format

    37 Anticipated Advantages of TetraBi Format Over First- and Second-Generation T-Cell Engagers nd st 1 Generation 2 Generation Abpro Antibody Bispecific Benefit Bispecific TetraBi Characteristics Stronger binding to the tumor cell, potentially leading Bivalent Binding to to increased efficacy and an

  38. Slide 38: Additional Key Team Members

    Additional Key Team Members 38

  39. Slide 39: Additional Key Team Members

    39 Additional Key Team Members Askar Kuchumov, PhD Awo Kankam Shaun Murphy, PhD Mengsha Wang, MBA VP of Business VP of Clinical Operations; VP of Immunology Director of Corporate Development Head of Program Management Development Lomonosov Moscow State, BS Cranfield UK, Brown PhD, Clark U MSc. Finan

  40. Slide 40: Additional Data for ABP-102 HER2/CD3 T-Cell Engager

    Additional Data for ABP-102 HER2/CD3 T-Cell Engager 40

  41. Slide 41: ABP-102: TetraBi antibodies exhibit selectivity in vitro

    ABP-102: engineered TetraBi antibodies exhibit selectivity in vitro, with potent 41 cytotoxicity on HER2-high cell lines and reduced killing of HER2-low cell lines HER2 expression level High Intermediate Trastuzumab binding by flow cytometry results in a 1 range of HER2 expressing cancer cell lines.

  42. Slide 42: ABP-102: functional selectivity for T cell activation

    ABP-102: engineered TetraBi antibodies exhibit functional selectivity for T cell 42 activation, including reduced cytokine release for HER2-low expressing cell lines HER2 high HER2 low ABP-102-mediated PBMC cytotoxicity of HER2-high (SKBR3) ABP-102-mediated cytokine release (IL-2, IFNg, IL-6, TNFa)

  43. Slide 43: Additional Data for ABP-201 VEGF/ANG-2 Bispecific Antibodies

    Additional Data for ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODIES 43

  44. Slide 44: ABP-201 Exhibits Favorable PK Compared with Vabysmo

    44 ABP-201 Exhibits Favorable PK Compared with Vabysmo 1 Faricimab(RG7716) 0.5 mg dose in Cyno PK parameter Unit Serum Aqueous C µg/ml 3.8 99 max t h 24 72 ABP-201 PK in max t h 89.3 68 1/2 Rabbit t h 672 672 last AUC (ug*h)/ml 295 18100 0-tlast AUC (ug*h)/ml 296 18200 0-inf F % 12.7 N/A vs. 2 ABP-2

  45. Slide 45: ABP-201 Exhibits Favorable PK Compared with Eylea

    45 ABP-201 Exhibits Favorable PK Compared with Eylea 1 ABP-201 0.2mg dose in Rabbit PK parameter Unit Serum Aqueous Vitreous Retina C µg/ml 0.415 14.374 183.357 8.457 max t h 48 48 1 24 max t h 38 108 82 106 1/2 AUC (ug*h)/ml 52 2529 36922 1777 0-tlast AUC (ug*h)/ml 55 2557 37027 1795 0-inf MRT (h)

  46. Slide 46: Certain Risks Related to ACAB, Abpro and the Business Combination

    46 Certain Risk Related to ACAB, Abpro and the Business Combination All references to the “Company,” “we,” “us” or “our” refer to the business of Abpro Corporation. and its subsidiaries, taken as a whole, unless the context otherwise requires. The risks noted below are not exhaustive and are qualifi

  47. Slide 47: Thank you!

    Mission: Developing antibody therapies to improve the lives of patients Thank you! facing severe and life- threatening diseases https://abpro.com/ ABPRO CORPORATION IR@abpro.com 68 Cummings Park, Woburn, MA 01801

Abpro — SPAC Merger (January 2024) on 6ix